Ha respondido al tema Oryzon Genomics (ORY)
Ir a respuesta
En definitiva, aunque los resultados mejoran en los biomarcadores no se ve su correlación en los test de memoria..los científicos andan perdidos..Me quedo con este últimoRasagilineA Parkinson’s disease drug showed some signs of efficacy in people with AD, according to results from a small proof-of-concept study of rasagiline presented by Dawn Matthews of ADM Diagnostics in Northbrook, Illinois. The drug inhibits monoamine oxidase B (MAOB), an enzyme that promotes the breakdown of dopamine and thus boosts dopaminergic activity in people with PD. Elevated MAOB levels have been detected around Aβ plaques in the AD brain, and the enzyme reportedly generates reactive oxygen species and even promotes amyloidogenic processing of APP, casting it as a candidate target.Run at the Cleveland Clinics in Las Vegas and Cleveland, the trial enrolled 50 people with diagnoses of mild to moderate AD, who had an AD-like pattern of metabolic dysfunction as indicated by FDG-PET. No Aβ- or tau-based biomarkers were used to confirm their diagnoses at screening. Participants took 0.5 mg rasagiline or placebo for the first four weeks, followed by 1 mg rasagiline, or placebo, for 20 weeks. Forty-three people completed the trial, which used change in FDG-PET from baseline to 24 weeks as its primary endpoint. Exploratory measures included tau-PET and several cognitive measures.The trial met its primary endpoint, Matthews reported. In the placebo group, glucose metabolism waned in prespecified frontal, anterior cingulate, and striatal regions over the 24-week trial. Metabolism slipped significantly less, or hardly at all, in these regions in the rasagiline group. On clinical measures, the rasagiline group posted significant improvements on the Quality of Life-AD (QOL-AD) test. They also trended toward better performance on six out of seven other cognitive tests, including the Controlled Oral Word Association Test (COWAT), the ADAS-Cog, MMSE, CGIC, Digit Span, and NPI.Matthews reported interactions between some of the outcome measures, saying that quality-of-life improvement correlated with FDG-PET uptake in the anterior cingulate, while improvement on the COWAT and digit span tests correlated with improved metabolism in the middle frontal regions. A higher tau-PET burden at baseline correlated with the degree of subsequent slippage on the MMSE for those in the placebo group, and with a larger treatment effect for those in the rasagiline group. Matthews said the findings warrant a larger trial.Ory-2001 es un inhibidor de MAO-B y además actúa sobre la LSD1. No muestran resultados sobre el tau o AB42 pero 6 de 7 test cognitivos muestran mejoría..sin duda muy alentador para los resultados de Oryzon en Abrilhttps://www.nj.com/healthfit/2019/10/heres-a-much-needed-dose-of-good-news-in-the-quest-to-cure-alzheimers.html